Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax Pharmaceuticals (NASDAQ: SNDX) announced inducement equity awards granted on February 1, 2026 under its 2023 Inducement Plan. The company granted options to purchase up to 11,600 shares to two new employees.
The options vest over four years: 25% after one year and the remainder monthly (1/48th) over the following 36 months, subject to continued service.
Syndax (Nasdaq: SNDX) reported preliminary, unaudited 4Q25 and full‑year 2025 results and business updates ahead of its J.P. Morgan presentation on Jan 12, 2026.
Key figures: preliminary Revuforj net revenue of $44M in 4Q25 and $125M for 2025, Revuforj net revenue up ~38% in 4Q25 vs 3Q25; preliminary Niktimvo net revenue of $56M in 4Q25 and $152M for 2025. Year‑end cash and marketable securities approx. $394M. 2026 expense outlook: R&D plus SG&A ~$400M (ex‑$50M stock comp). Several Phase 2/3 trials and access programs planned for 2026.
Syndax (Nasdaq: SNDX) and the World Orphan Drug Alliance announced a multi-regional Managed Access Program to expand patient access to Revuforj (revumenib) outside the U.S. The program will operate where local rules permit and funding is secured and launches in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa. WODA will administer named-patient supply through its network and the program will follow local regulatory and ethical frameworks. U.S. FDA approvals for Revuforj in specified relapsed/refractory KMT2A‑translocated and NPM1‑mutated acute leukemias are noted. Physicians should contact medinfo@syndax.com for details; patients must contact their physician.
Syndax (Nasdaq: SNDX) announced that Chief Executive Officer Michael A. Metzger will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. A live webcast will be available in the company's Investor section at www.syndax.com, and a replay will be accessible for a limited time.
Syndax (Nasdaq: SNDX) announced that Revuforj (revumenib) was named Best New Drug at the Scrip Awards 2025.
Revuforj is a first-in-class menin inhibitor that received FDA approval in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation in patients one year and older, and a second FDA approval in October 2025 for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in patients one year and older who have no satisfactory alternative treatment options.
The award recognizes perceived therapeutic advance and follows the recent regulatory expansion, which company leadership described as validation of its menin-inhibition program and patient focus.
Syndax (NASDAQ: SNDX) presented 12 Revuforj (revumenib) abstracts at ASH 2025 covering real-world, post‑HSCT maintenance, and combination trials in NPM1m, KMT2Ar and NUP98r acute leukemias.
Key disclosed results: real‑world ORR 77% (10/13) and 75% MRD negativity; pediatric post‑HSCT maintenance cohort: 100% alive and 90% relapse‑free at median 19 months; Phase 2 SAVE (revumenib+venetoclax+HMA) in newly diagnosed unfit patients: ORR 86% (18/21), CR 76% (16/21), 100% MRD negativity among responders; Phase 1 with intensive chemo: ORR 96% (25/26), CRc 92% (24/26), MRD‑negative CR 86% (12/14).
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on December 1, 2025 to a newly hired employee under its 2023 Inducement Plan.
The awards permit purchase of up to 15,500 shares of common stock. Options vest over a four-year schedule: 25% of the shares vest on the one-year anniversary of the vesting commencement date, then 1/48th of the shares vest monthly for the remaining 36 months, subject to continued service.
Syndax (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast will be available in the company’s Investor section at www.syndax.com, and a replay will be posted for a limited time.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards on November 1, 2025, granting options to purchase up to 143,500 shares of common stock to four new employees under its 2023 Inducement Plan.
The options vest over four years: 25% at the one-year anniversary of the vesting commencement date and 1/48th monthly thereafter for the remaining 36 months, subject to continued service through each vesting date.
Syndax (Nasdaq: SNDX) reported $45.9M total revenue for 3Q25, including $32.0M Revuforj net revenue and $13.9M collaboration revenue from Niktimvo. Revuforj prescriptions rose ~25% QoQ (~850 scripts) and Revuforj received FDA approval on Oct 24, 2025 and NCCN category 2A listing for R/R NPM1m AML. Incyte reported $45.8M Niktimvo net sales; Syndax recorded 50% product contribution. Cash, cash equivalents and investments were $456.1M, which the company expects will fund it to profitability. Reported 3Q25 net loss was $60.7M. Conference call held Nov 3, 2025.